Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02281084

Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 
Evaluate the safety and efficacy of CC-496 and Durvalumab in Subjects with Myelodysplastic Syndromes who failed to achieve an objective response post iHMA treatment
Status: 
Recruiting
Study Date: 
Wed, 07/01/2015 to Sun, 07/01/2018
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: CC-486 (ORAL AZACITIDINE) 200 mg CC-486 (Oral Azacitidine) will be given for the first 21 days of each 28-day treatment cycle Other Name: CC-486 Drug: Durvalumab